Ik ben benieuwd wat de prijsstelling gaat worden van Leronlimab in de ontwikkelde landen na 10 juli, (July 10 is the date on which the agency will reveal the completion timeline for the biologics license application (BLA) review of leronlimab, and CytoDyn is going to be issued with a Prescription Drug User Fee Act date).
KEY FACTS (Prijsstelling Remdesivir)
In a statement on Monday, Gilead said it will charge governments in the developed world—including programs like Medicare in the U.S.—$2,340 for a typical five-day treatment course, or $390 per vial for six vials.
Private insurance companies in the United States will pay more: $3,120 for a typical course of treatment, or $520 per vial.
Countries in the developing world, where Gilead has licensed the drug to generic manufacturers, will pay significantly less.
Gilead estimates that the drug will reduce hospital costs by $12,000 per patient based on data showing that Covid-19 patients taking remdesivir were discharged from the hospital four days earlier than those undergoing a standard treatment plan.
Given those results, Gilead said its pricing plan is “well below” the drug’s value.
In May, Gilead donated its entire remdesivir stockpile of 1.5 million doses to the U.S. government to allocate on an as-needed basis through the end of June.
Gilead will begin charging for remdesivir in July, CNBC reports.
Crucial quote
“Remdesivir, our investigational treatment, is the first antiviral to have demonstrated patient improvement in clinical trials for Covid-19, and there is no playbook for how to price a new medicine in a pandemic,” Gilead CEO Daniel O’Day wrote in an open letter on Monday. O’Day said decisions over pricing came with “significant responsibility.”
Big number
2.7%. That’s how much shares of Gilead jumped on Monday’s news in premarket trading.
Key background
Remdesivir was authorized for emergency use by the Food and Drug Administration in May after the drug showed promising results in early clinical trials. That authorization is temporary, however, and does not mean that the drug has been officially approved by the FDA. The normal approval process can take years. While clinical trial data from a National Institute of Allergy and Infectious Diseases study has shown that remdesivir shortens recovery times in some patients, another study from China found no statistically significant improvement in recovery time.